Acquisition

Merck to Acquire Cidara Therapeutics for $9.2 Billion, Gaining Late-Stage Antiviral Agent CD388

By BiotechReality Business Intelligence Desk
15 November 2025

Merck has announced a definitive agreement to acquire Cidara Therapeutics for approximately $9.2 billion in an all-cash deal. The strategic acquisition centers on Cidara’s lead candidate, CD388, a potentially first-in-class, long-acting antiviral designed for the universal prevention of influenza A and B, which is currently in Phase 3 trials. The transaction is expected to close in the first quarter of 2026.

Business Healthcare & Pharmaceuticals News

Pfizer Acquires Metsera in $4.9 Billion Deal, Bolsters Obesity Drug Portfolio

By Ajmal Aseem
23 September 2025

Pfizer has announced a definitive agreement to acquire clinical-stage biopharmaceutical company Metsera in a deal valued at an initial $4.9 billion, with the potential for an additional $2.4 billion in milestone payments. The acquisition is a strategic move to re-enter the lucrative weight-loss drug market by adding Metsera’s next-generation obesity and cardiometabolic disease treatments, including promising oral and injectable therapies, to Pfizer’s pipeline.

Business News

AbbVie Completes $2.1 Billion Acquisition of Capstan Therapeutics: Advancing First-in-Class In Vivo CAR-T Technology for Autoimmune Diseases

By Athulya B S
19 August 2025

AbbVie has finalized its acquisition of Capstan Therapeutics, gaining access to a groundbreaking in vivo tLNP CAR-T cell therapy and proprietary RNA delivery platform for B cell-mediated autoimmune diseases.

Tag: Acquisition

Merck to Acquire Cidara Therapeutics for $9.2 Billion, Gaining Late-Stage Antiviral Agent CD388

Pfizer Acquires Metsera in $4.9 Billion Deal, Bolsters Obesity Drug Portfolio

AbbVie Completes $2.1 Billion Acquisition of Capstan Therapeutics: Advancing First-in-Class In Vivo CAR-T Technology for Autoimmune Diseases

Areas Covered

Discover More

Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN

LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C

GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline

Johnson & Johnson Q2 2026 Analysis: Company Reports $25.3 Billion in Sales, Raises Full-Year Outlook

Merck’s Erbitux BRAF V600E mCRC Regimen Gets EU Approval for First-Line Treatment

AstraZeneca Zegfrovy Deal: AstraZeneca Licenses Dizal’s Oral EGFR Inhibitor for Lung Cancer in Up to $1.5 Billion Agreement